Bisirna Therapeutics (Suzhou) Co., Ltd.
Bisirna Therapeutics (Suzhou) Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome | Not yet recruiting | Phase 3 | 2026-09-11 | NCT07816237 | |
| Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a) | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, metabolic disease | Active, not recruiting | Phase 1 | 2026-08-19 | NCT07551505 | |
| A Phase I Clinical Study of VSA012 in Healthy Volunteers | Healthy Volunteers | Active, not recruiting | Phase 1 | 2026-05-04 | NCT06766929 |